Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

DRUG ADVANCES

Professional illustration by Patrick Lane, ScEYEnce Studios.

EXCEPTIONAL CASE REPORT

STIMULUS REPORTS

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

GENE THERAPY

HEALTH SERVICES AND OUTCOMES

Johanne Rozema,on behalf of the HemoBase Population Registry Consortium,Mels Hoogendoorn,on behalf of the HemoBase Population Registry Consortium,Robby Kibbelaar,on behalf of the HemoBase Population Registry Consortium,Eva van den Berg,on behalf of the HemoBase Population Registry Consortium,Nic Veeger,on behalf of the HemoBase Population Registry Consortium,Eric van Roon,on behalf of the HemoBase Population Registry Consortium

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Damien Luque Paz,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jérémie Riou,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Emmanuelle Verger,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Bruno Cassinat,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Aurélie Chauveau,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Christophe Ianotto,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Brigitte Dupriez,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Françoise Boyer,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Maxime Renard,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Mansier,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Anne Murati,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jérôme Rey,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Gabriel Etienne,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Véronique Mansat-De Mas,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Suzanne Tavitian,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Nibourel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Stéphane Girault,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Yannick Le Bris,on behalf of the French Intergroup of Myeloproliferative Neoplasms,François Girodon,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Dana Ranta,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Claude Chomel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pascale Cony-Makhoul,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pierre Sujobert,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Margot Robles,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Raouf Ben Abdelali,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Kosmider,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Laurane Cottin,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Lydia Roy,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Ivan Sloma,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Fabienne Vacheret,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Mathieu Wemeau,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pascal Mossuz,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Borhane Slama,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Vincent Cussac,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Guillaume Denis,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Anouk Walter-Petrich,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Barbara Burroni,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Nathalie Jézéquel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Stéphane Giraudier,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Eric Lippert,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Gérard Socié,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Jacques Kiladjian,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Valérie Ugo,on behalf of the French Intergroup of Myeloproliferative Neoplasms
Sebastiano Rontauroli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sara Castellano,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Paola Guglielmelli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Roberta Zini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elisa Bianchi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elena Genovese,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Chiara Carretta,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sandra Parenti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sebastian Fantini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Selene Mallia,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Lara Tavernari,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Stefano Sartini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Margherita Mirabile,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Carmela Mannarelli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Francesca Gesullo,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Annalisa Pacilli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Daniela Pietra,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elisa Rumi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Silvia Salmoiraghi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Barbara Mora,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Laura Villani,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Andrea Grilli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Vittorio Rosti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Giovanni Barosi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Francesco Passamonti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Alessandro Rambaldi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Luca Malcovati,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Mario Cazzola,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Silvio Bicciato,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Enrico Tagliafico,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Alessandro M. Vannucchi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Rossella Manfredini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

Laura H. Bukkems,for the OPTI-CLOT Study Group,Jessica M. Heijdra,for the OPTI-CLOT Study Group,Nico C. B. de Jager,for the OPTI-CLOT Study Group,Hendrika C. A. M. Hazendonk,for the OPTI-CLOT Study Group,Karin Fijnvandraat,for the OPTI-CLOT Study Group,Karina Meijer,for the OPTI-CLOT Study Group,Jeroen C. J. Eikenboom,for the OPTI-CLOT Study Group,Britta A. P. Laros-van Gorkom,for the OPTI-CLOT Study Group,Frank W. G. Leebeek,for the OPTI-CLOT Study Group,Marjon H. Cnossen,for the OPTI-CLOT Study Group,Ron A. A. Mathôt,for the OPTI-CLOT Study Group

TRANSPLANTATION

COMMENTARY

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals